-
IN EDITION MEDICUS WAS PUBLISHED
MULTIDISCIPLINARY APPROACH to Oesophageal and gastric cancer
EDITOR: RADKA OBERMANNOVA
ASSOCIATE EDITORS: FLORIAN LORDICK, LUBOS PETRUZELKA
Actual articles
Treatment of lung metastases in prostate cancer – case reports
05/2021 MUDr. Eva Kindlová
Prostate cancer is one of the most common cancers in men. Approximately 20 % of diagnosed patients had already developed metastases, in others the tumor may generalize after the locoregional treatment. The most frequent are bone and lymph nodes metastases, less frequented sites of metastases are lungs, liver, and other organs. The ways of treatment depend on whether the tumor is metastatic hormone-naive prostate cancer (mHSPC) or metastatic castration-resistant prostate cancer (mCRPC). Both local and systemic therapies are possible for treating lung metastases. Modalities of local therapy are surgical therapy and radiotherapy; hormone therapy, chemotherapy and ARTA therapy can be administered as systemic therapy. It is necessary to choose the optimal sequence of modalities and even use several lines of therapy to reach the best response. That can result in significant improvement of patienťs life expectancy and his quality of life as well.
ENTIRE ARTICLE
Prostate cancer is one of the most common cancers in men. Approximately 20 % of diagnosed patients had already developed metastases, in others the tumor may generalize after the locoregional treatment. The most frequent are bone and lymph nodes metastases, less frequented sites of metastases are lungs, liver, and other organs. The ways of treatment depend on whether the tumor is metastatic hormone-naive prostate cancer (mHSPC) or metastatic castration-resistant prostate cancer (mCRPC). Both local and systemic therapies are possible for treating lung metastases. Modalities of local therapy are surgical therapy and radiotherapy; hormone therapy, chemotherapy and ARTA therapy can be administered as systemic therapy. It is necessary to choose the optimal sequence of modalities and even use several lines of therapy to reach the best response. That can result in significant improvement of patienťs life expectancy and his quality of life as well.
Medullary thyroid carcinoma – case reports
05/2021 MUDr. Andrea Jurečková
Two case reports of patients with metastatic medullary thyroid carcinoma treated with tyrosine kinase inhibitors as a 1st line treatment are presented. The effectiveness of the treatment is compared - long-term treatment response in patient with early detected metastatic disease versus quick progression in patient with late diagnosis of advanced carcinoma and large proportion of metastatic lesions.
ENTIRE ARTICLE
Two case reports of patients with metastatic medullary thyroid carcinoma treated with tyrosine kinase inhibitors as a 1st line treatment are presented. The effectiveness of the treatment is compared - long-term treatment response in patient with early detected metastatic disease versus quick progression in patient with late diagnosis of advanced carcinoma and large proportion of metastatic lesions.
Coincidence of oropharyngeal carcinoma and systemic progressive sclerosis in a 47‑year‑old patient – case report
05/2021 MUDr. Kateřina Licková; MUDr. Aleš Čoček, Ph.D.
Systemic progressive sclerosis is an autoimmune disease of unclear etiology characterized by vasculopathy and fibrosis. The incidence of malignancies in patients with this serious disease is higher than in the general population. The cause of this predisposition is not yet clearly defined. In our case we present a patient with systemic progressive sclerosis who was diagnosed with oropharyngeal carcinoma. The aim of this work is to draw attention to the complications in differential diagnosis and therapy in concurrent systemic autoimmune and cancer.
ENTIRE ARTICLE
Systemic progressive sclerosis is an autoimmune disease of unclear etiology characterized by vasculopathy and fibrosis. The incidence of malignancies in patients with this serious disease is higher than in the general population. The cause of this predisposition is not yet clearly defined. In our case we present a patient with systemic progressive sclerosis who was diagnosed with oropharyngeal carcinoma. The aim of this work is to draw attention to the complications in differential diagnosis and therapy in concurrent systemic autoimmune and cancer.